Search Results - "Salwender, Hans"

Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma by Berghaus, Natalie, Schreiner, Sarah, Poos, Alexandra M, Raab, Marc S, Goldschmidt, Hartmut, Mai, Elias K, Salwender, Hans-Jürgen, Bernhard, Helga, Thurner, Lorenz, Müller-Tidow, Carsten, Weinhold, Niels, Hegenbart, Ute, Schönland, Stefan O, Huhn, Stefanie

“…Light chain amyloidosis (AL) is one of the most common forms of systemic amyloidosis and is caused by the deposition of insoluble fibrils derived from…”
Get full text

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project by D'Agostino, Mattia, Cairns, David A, Lahuerta, Juan José, Wester, Ruth, Bertsch, Uta, Waage, Anders, Zamagni, Elena, Mateos, María-Victoria, Dall'Olio, Daniele, van de Donk, Niels W C J, Jackson, Graham, Rocchi, Serena, Salwender, Hans, Bladé Creixenti, Joan, van der Holt, Bronno, Castellani, Gastone, Bonello, Francesca, Capra, Andrea, Mai, Elias K, Dürig, Jan, Gay, Francesca, Zweegman, Sonja, Cavo, Michele, Kaiser, Martin F, Goldschmidt, Hartmut, Hernández Rivas, Jesús María, Larocca, Alessandra, Cook, Gordon, San-Miguel, Jesús F, Boccadoro, Mario, Sonneveld, Pieter

“…Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the…”
Get full text

Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients by Weinhold, Niels, Salwender, Hans J, Cairns, David A, Raab, Marc S, Waldron, George, Blau, Igor W, Bertsch, Uta, Hielscher, Thomas, Morgan, Gareth J, Jauch, Anna, Davies, Faith E, Hänel, Mathias, Cook, Gordon, Scheid, Christoph, Houlston, Richard, Goldschmidt, Hartmut, Jackson, Graham, Kaiser, Martin F

Get full text

Selective elimination of immunosuppressive T cells in patients with multiple myeloma by Awwad, Mohamed H. S., Mahmoud, Abdelrahman, Bruns, Heiko, Echchannaoui, Hakim, Kriegsmann, Katharina, Lutz, Raphael, Raab, Marc S., Bertsch, Uta, Munder, Markus, Jauch, Anna, Weisel, Katja, Maier, Bettina, Weinhold, Niels, Salwender, Hans Jürgen, Eckstein, Volker, Hänel, Mathias, Fenk, Roland, Dürig, Jan, Brors, Benedikt, Benner, Axel, Müller-Tidow, Carsten, Goldschmidt, Hartmut, Hundemer, Michael

“…Elimination of suppressive T cells may enable and enhance cancer immunotherapy. Here, we demonstrate that the cell membrane protein SLAMF7 was highly expressed…”
Get full text

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial by SONNEVELD, Pieter, SCHMIDT-WOLF, Ingo G. H, WEISEL, Katja C, WITTEBOL, Shulamiet, BOS, Gerard M. J, STEVENS-KROEF, Marian, SCHEID, Christof, PFREUNDSCHUH, Michael, HOSE, Dirk, JAUCH, Anna, DER VELDE, Helgi Van, RAYMAKERS, Reinier, DER HOLT, Bronno Van, SCHAAFSMA, Martijn R, KERSTEN, Marie-Jose, MARWIJK-KOOY, Marinus Van, DUEHRSEN, Ulrich, LINDEMANN, Walter, WIJERMANS, Pierre W, LOKHORST, Henk M, GOLDSCHMIDT, Hartmut M, EL JARARI, Laila, BERTSCH, Uta, SALWENDER, Hans, ZWEEGMAN, Sonja, VELLENGA, Edo, BROYL, Annemiek, BLAU, Igor W

“…We investigated whether bortezomib during induction and maintenance improves survival in newly diagnosed multiple myeloma (MM). In all, 827 eligible patients…”
Get full text

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial by Leypoldt, Lisa B., Besemer, Britta, Asemissen, Anne Marie, Hänel, Mathias, Blau, Igor Wolfgang, Görner, Martin, Ko, Yon-Dschun, Reinhardt, Hans Christian, Staib, Peter, Mann, Christoph, Lutz, Raphael, Munder, Markus, Graeven, Ullrich, Peceny, Rudolf, Salwender, Hans, Jauch, Anna, Zago, Manola, Benner, Axel, Tichy, Diana, Bokemeyer, Carsten, Goldschmidt, Hartmut, Weisel, Katja C.

Get full text

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE by Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, Weisel, Katja

“…The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the…”
Get full text

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial by Goldschmidt, Hartmut, Mai, Elias K., Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Bertsch, Uta, Hielscher, Thomas, Merz, Maximilian, Munder, Markus, Lindemann, Hans-Walter, Hügle-Dörr, Barbara, Tichy, Diana, Giesen, Nicola, Hose, Dirk, Seckinger, Anja, Huhn, Stefanie, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Rabold, Bernhard, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Hillengass, Jens, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Salwender, Hans J.

“…The MM5 trial aimed at demonstrating a progression-free survival (PFS) difference in continued vs. response-adapted (in case of complete response, CR)…”
Get full text

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients by Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Zweegman, Sonja, Raab, Marc S., Munder, Markus, Pantani, Lucia, Mancuso, Katia, Brossart, Peter, Beksac, Meral, Blau, Igor W., Dürig, Jan, Besemer, Britta, Fenk, Roland, Reimer, Peter, van der Holt, Bronno, Hänel, Mathias, von Metzler, Ivana, Graeven, Ullrich, Müller-Tidow, Carsten, Boccadoro, Mario, Scheid, Christof, Dimopoulos, Meletios A., Hillengass, Jens, Weisel, Katja C., Cavo, Michele, Sonneveld, Pieter, Goldschmidt, Hartmut

“…Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction…”
Get full text

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A by SCHLENK, Richard F, DÖHNER, Konstanze, GRIMMINGER, Wolfgang, KOBBE, Guido, GLASMACHER, Axel, SALWENDER, Hans, KIRCHEN, Heinz, HAASE, Detlef, KREMERS, Stephan, MATZDORFF, Axel, BENNER, Axel, DÖHNER, Hartmut, MACK, Silja, STOPPEL, Michael, KIRALY, Franz, GÖTZE, Katharina, HARTMANN, Frank, HORST, Heinz A, KOLLER, Elisabeth, PETZER, Andreas

“…To assess the impact of allogeneic hematopoietic stem-cell transplantation (HSCT) from matched related donors (MRDs) and matched unrelated donors (MUDs) on…”
Get full text

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial by Goldschmidt, Hartmut, Mai, Elias K, Nievergall, Eva, Tichy, Diana, Besemer, Britta, Dürig, Jan, von Metzler, Ivana, Hänel, Mathias, Asemissen, Anne M, Heilmeier, Bernhard, Huhn, Stefanie, Kriegsmann, Katharina, Luntz, Steffen P, Holderried, Tobias A W, Trautmann-Grill, Karolin, Klaiber-Hakimi, Maika, Müller, Martin, Khandanpour, Cyrus, Knauf, Wolfgang, Scheid, Christof, Riesenberg, Hendrik, Thomalla, Jörg, Hoffmann, Martin, Raab, Marc S, Salwender, Hans J, Weisel, Katja C, Asemissen, Anne M, Behringer, Joachim, Bernhard, Helga, Bernhardt, Christiane, Bertsch, Uta, Besemer, Britta, Blau, Igor W, Debatin, Daniel, Dingeldein, Gerrit, Dürig, Jan, Ferstl, Barbara, Fronhoffs, Stefan, Fuhrmann, Stephan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Graeven, Ullrich, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Held, Gerhard, Hoffmann, Martin, Hopfer, Olaf, Huhn, Stefanie, Immenschuh, Peter, Kaddu-Mulindwa, Dominic, Khandanpour, Cyrus, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Köchling, Georg, Koenigsmann, Michael, Kostrewa, Philippe, Kraemer, Doris Maria, Kremers, Stephan, Kriegsmann, Katharina, La Rosée, Paul, Luntz, Steffen P, Mahlberg, Rolf, Mai, Elias K, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Müller, Martin, Neise, Michael, Nievergall, Eva, Nückel, Holger, Pönisch, Wolfram, Raab, Marc S, Reimer, Peter, Riecke, Armin, Riesenberg, Hendrik, Rummel, Mathias, Runde, Volker, Schaich, Markus, Schmitt, Stefan, Schöndube, Daniel, Schroers, Roland, Schwarzer, Andreas, Staib, Peter, Steiniger, Heike, Thomalla, Jörg, Tichy, Diana, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Trummer, Arne, Tschechne, Barbara, Verbeek, Walter, Weisel, Katja C, Whitlock, Bettina, Ziske, Carsten

“…Anti-CD38 monoclonal antibodies have consistently shown increased efficacy when added to standard of care for patients with multiple myeloma. We aimed to…”
Get full text

Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma by Mai, Elias K., Huhn, Stefanie, Miah, Kaya, Poos, Alexandra M., Scheid, Christof, Weisel, Katja C., Bertsch, Uta, Munder, Markus, Berlanga, Oscar, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Blau, Igor W., Hänel, Mathias, Salwender, Hans J., Benner, Axel, Raab, Marc S., Goldschmidt, Hartmut, Weinhold, Niels

“…Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed…”
Get full text

CD8+ CD28− regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study by Kriegsmann, Katharina, Ton, Gigi Nu Hoang Quy, Awwad, Mohamed H. S., Benner, Axel, Bertsch, Uta, Besemer, Britta, Hänel, Mathias, Fenk, Roland, Munder, Markus, Dürig, Jan, Blau, Igor W., Huhn, Stefanie, Hose, Dirk, Jauch, Anna, Mann, Christoph, Weinhold, Niels, Scheid, Christof, Schroers, Roland, von Metzler, Ivana, Schieferdecker, Aneta, Thomalla, Jörg, Reimer, Peter, Mahlberg, Rolf, Graeven, Ullrich, Kremers, Stephan, Martens, Uwe M., Kunz, Christian, Hensel, Manfred, Seidel-Glätzer, Andrea, Weisel, Katja C., Salwender, Hans J., Müller-Tidow, Carsten, Raab, Marc S., Goldschmidt, Hartmut, Mai, Elias K., Hundemer, Michael

Get full text

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective, phase II study by Kröger, Nicolaus, Wulf, Gerald, Hegenbart, Ute, Burchert, Andreas, Stelljes, Matthias, Gagelmann, Nico, Brecht, Arne, Kaufmann, Martin, Müller, Lutz, Ganser, Arnold, Wolf, Dominik, Bethge, Wolfgang, Bornhäuser, Martin, Kiehl, Michael, Wagner, Eva-Maria, Schmid, Christoph, Reinhardt, Hans Christian, Kobbe, Guido, Salwender, Hans, Heinicke, Thomas, Kropff, Martin, Heinzelmann, Marion, Ayuk, Francis, Trümper, Lorenz, Neubauer, Andreas, Völp, Andreas, Kluychnikov, Evgeny, Schönland, Stefan, Wolschke, Christine

“…The role of autologous-allogeneic tandem stem cell transplantation (alloTSCT) followed by maintenance as upfront treatment for multiple myeloma is…”
Get full text

Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age by Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., Goldschmidt, Hartmut

“…Intensive upfront therapy in newly-diagnosed multiple myeloma (MM) including induction therapy (IT), high-dose melphalan (MEL200), and autologous blood stem…”
Get full text

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial by Salwender, Hans, Elmaagacli, Ahmet, Merz, Maximilian, Miah, Kaya, Benner, Axel, Haenel, Mathias, Jehn, Christian, Mai, Elias K., Bertsch, Uta, Blau, Igor W., Scheid, Christof, Hose, Dirk, Seckinger, Anja, Jauch, Anna, Raab, Marc S., Luntz, Steffen P., Besemer, Britta, Munder, Markus, Brossart, Peter, Fuhrmann, Stephan, Lindemann, Hans-Walter, Weisel, Katja, Duerig, Jan, Goldschmidt, Hartmut

Get full text

RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma by Emde-Rajaratnam, Martina, Beck, Susanne, Benes, Vladimir, Salwender, Hans, Bertsch, Uta, Scheid, Christoph, Hänel, Mathias, Weisel, Katja, Hielscher, Thomas, Raab, Marc S, Goldschmidt, Hartmut, Jauch, Anna, Maes, Ken, De Bruyne, Elke, Menu, Eline, De Veirman, Kim, Moreaux, Jérôme, Vanderkerken, Karin, Seckinger, Anja, Hose, Dirk

“…Immunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing…”
Get full text

Molecular Long-Term Analysis of the GMMG-HD4 Trial in Multiple Myeloma-Patterns of Association of Chromosomal Aberrations with Response and Proliferation Determining Survival in Selecting Treatments in View of Limited Resources in Low- and Middle-Income Countries by Seckinger, Anja, Salwender, Hans, Martin, Hans, Scheid, Christof, Hielscher, Thomas, Bertsch, Uta, Hummel, Manuela, Jauch, Anna, Knauf, Wolfgang, Emde-Rajaratnam, Martina, Beck, Susanne, Neben, Kai, Dührig, Jan, Lindemann, Walter, Schmidt-Wolf, Ingo G H, Hänel, Mathias, Blau, Igor W, Weisel, Katja, Weinhold, Niels, Raab, Marc S, Goldschmidt, Hartmut, Choon-Quinones, Mimi, Hose, Dirk

“…Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; =…”
Get full text

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial by Klein, Eva-Maria, Tichy, Diana, Salwender, Hans, Mai, Elias, Duerig, Jan, Weisel, Katja, Benner, Axel, Bertsch, Uta, Akhavanpoor, Mabast, Besemer, Britta, Munder, Markus, Lindemann, Hans-Walter, Hose, Dirk, Seckinger, Anja, Luntz, Steffen, Jauch, Anna, Elmaagacli, Ahmet, Fuhrmann, Stephan, Brossart, Peter, Goerner, Martin, Bernhard, Helga, Raab, Marc, Blau, Igor, Haenel, Mathias, Scheid, Christof, Goldschmidt, Hartmut

“…We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM)…”
Get full text

Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age by Mai, Elias K., Miah, Kaya, Bertsch, Uta, Dürig, Jan, Scheid, Christof, Weisel, Katja C., Kunz, Christina, Munder, Markus, Lindemann, Hans-Walter, Merz, Maximilian, Hose, Dirk, Jauch, Anna, Seckinger, Anja, Luntz, Steffen, Sauer, Sandra, Fuhrmann, Stephan, Brossart, Peter, Elmaagacli, Ahmet, Goerner, Martin, Bernhard, Helga, Hoffmann, Martin, Raab, Marc S., Blau, Igor W., Hänel, Mathias, Benner, Axel, Salwender, Hans J., Goldschmidt, Hartmut

Get full text